Phase III Trial of Vinorelbine+BIBW 2992 vs Vinorelbine+Herceptin in BC Patients After Failing Herceptin Treatment - Trial SLCTR_2012_003
Access comprehensive clinical trial information for SLCTR_2012_003 through Pure Global AI's free database. This Phase 3 trial is sponsored by Boehringer Ingelheim India (Pvt) Ltd and is currently Terminated. The study focuses on Metastatic Breast Cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
SLCTR_2012_003
Phase 3
Terminated
Trial Details
Sri Lanka Clinical Trials Registry • SLCTR_2012_003
Phase III Trial of Vinorelbine+BIBW 2992 vs Vinorelbine+Herceptin in BC Patients After Failing Herceptin Treatment
An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment
Study Focus
Interventional
Sponsor & Location
Boehringer Ingelheim India (Pvt) Ltd
Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, France, Germany
Timeline & Enrollment
Phase 3
Mar 11, 2012
N/A
ICD-10 Classifications
Malignant neoplasm of breast
Malignant neoplasm of breast
Malignant neoplasm: Breast, unspecified
Malignant neoplasm: Central portion of breast
Malignant neoplasm: Overlapping lesion of breast
Data Source
Sri Lanka Clinical Trials Registry
SLCTR_2012_003
Non-Device Trial